Showing 1921-1930 of 4065 results for "".
Early Axial Length Changes Signal Red Light Therapy Success in Myopia Control
https://reachmd.com/programs/eye-on-ocular-health/early-axial-length-changes-signal-red-light-therapy-success-in-myopia-control/36281/Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
https://reachmd.com/programs/cme/cardio-renal-metabolic-care-evidence-based-therapies-optimize-outcomes/56917/On-demand webcast on best practices for optimizing guideline-directed medical therapy in cardiovascular-renal-metabolic (CRM) care and employing SGLT2 inhibitors to treat patients with CRM conditions, including heart failure.The Crohn’s & Colitis Foundation's Camp Oasis: A Clinician's Perspective
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/the-crohns-colitis-foundations-camp-oasis-a-clinicians-perspective/10083/Dr. Philip Stein talks with clinicians Dr. Neilanjan Nandi and Susan Peck about their experiences at CCF's Camp Oasis.Building Bridges, Closing Gaps in NASH Care: The Pivotal Role of Gastroenterologists
https://reachmd.com/programs/cme/building-bridges-closing-gaps-in-nash-care-the-pivotal-role-of-gastroenterologists/15671/Are you up to date on the NAFLD clinical care pathway to provide optimal treatment for your patients?SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
https://reachmd.com/clinical-practice/cardiology/spirit-hf-does-spironolactone-improve-outcomes-in-hfpef-and-hfmref/57081/Review SPIRIT-HF findings evaluating spironolactone outcomes and safety in patients with HFpEF and HFmrEF.The Crohn’s & Colitis Foundation's Camp Oasis: A Patient's Perspective
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/the-crohns-colitis-foundations-camp-oasis-a-patients-perspective/10084/Dr. Philip Stein talks with Claire Griffin and Bill Johnson, patients and counselors at CCF's Camp Oasis, about their unique experiences.Inside the Cataracts Studio: Advanced Fluidics, Ergonomics, and Techniques for Complex Cases - Introducing Robotic SLACS
https://reachmd.com/programs/cme/inside-the-cataracts-studio-advanced-fluidics-ergonomics-and-techniques-for-complex-cases-introducing-robotic-slacs/33177/Explore SLACS for cataract surgery, which features a robotic femtosecond laser integrated into the operating suite that can be utilized for complex cases.Treatment Patterns and MRA Use in Patients with HFmrEF/HFpEF: Insights From FRAME-HF and IRIS HF
https://reachmd.com/clinical-practice/cardiology/heart-failure-treatment-trends-insights-from-frame-hf-and-iris-hf/57080/Review ESC Heart Failure 2026 data on treatment patterns and MRA use in HF across the FRAME-HF and IRIS-HF cohorts.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
https://reachmd.com/clinical-practice/cardiology/evolocumab-in-patients-without-significant-atherosclerosis-and-with-diabetes-a-cardiology-perspective-on-vesalius-cv/56744/New VESALIUS-CV data show broad cardiovascular benefits of evolocumab in high-risk primary prevention patients with diabetes and no atherosclerosis.